Taste of Medicines in Children
- Conditions
- Medication AdherenceMedication Reaction
- Registration Number
- NCT04220918
- Lead Sponsor
- Children's Hospital of Philadelphia
- Brief Summary
Some but not all children will refuse to take medicine because of its taste, which can lead to substantial worsening of disease, antibiotic resistance, increased health care costs, and even death. The investigators are systematically assessing individual variation in the taste of liquid clindamycin among genotyped pediatric patients prescribed clindamycin for standard of care treatment, to determine whether (1) genetic variation underlies differences in taste ratings of the antibiotic; (2) initial taste responses, genetics, or both predict likelihood of side effects and medication non-adherence.
- Detailed Description
Taste plays an integral role in whether a child accepts a medicine. Some children will like the taste of a given medicine and complete the full course of treatment, whereas others will strongly reject its taste, suffer taste-modulated side effects, or both. This study will systematically measure initial palatability and reactions to the first dose of an antibiotic (clindamycin, liquid formulation) by pediatric patients who are receiving clindamycin as part of their standard of care treatment. Saliva will be collected from all patients for GWAS. Taste response, tolerance of the medication, adherence and clinical outcomes will be assessed. Subjects will be followed to determine if they complete the prescribed medication regimen (adherence) and/or experience side effects (tolerability). Because medication-specific side effects have patient-specific variability, the investigators will determine whether the child's initial taste responses, genes, or both predict subsequent side effects and medication adherence.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 136
- Children age 3 to 12
- Child being treated in Children's Hospital of Philadelphia
- Being prescribed clindamycin liquid
- Parental/guardian permission (informed consent) and if appropriate, child assent
- Parent age 18 or older, or a minor permitted by state law to consent for their own participation and for the participation of their child
- Parent must have primary responsibility for the patient including biologic parents and adoptive parents (if legally allowed to consent to research)
- Parent must be English speaking and able to understand study materials
- Unwilling or unable to produce saliva sample
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Palatability of clindamycin liquid 10 minutes after dosing Taste ratings by the child using a hedonic face scale (scale = 1-5; 1=dislike a lot, 2=dislike a little, 3=neither like nor dislike, 4=like a little, 5=like a lot)
Taste reactivity of clindamycin liquid Immediately after dosing for a total of 10 minutes Digital recordings will be analyzed for child's facial and body movements by blinded and trained reviewers
- Secondary Outcome Measures
Name Time Method Treatment adherence 5-14 day treatment regimen given two-three times a day Adherence to treatment course will be measured by parental report aided by a medication diary
Clinical outcomes within 1 week after completion of therapy Clinical outcome of infection (cured on clindamycin vs not cured on clindamycin) will be measured through medical record review and parental report during follow-up interview
Medication tolerance and side effects with clindamycin use 5-14 day treatment regimen given two-three times a day Medication tolerance and side effects to medication will be measured through direct observation, parent report, and medical records
Genome-wide association 3 years salivary DNA
Trial Locations
- Locations (1)
Children's Hospital of Philadelphia
🇺🇸Philadelphia, Pennsylvania, United States